Oslo, Norway 7 May 2021 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 28 May 2021 at 10:00am (CEST).
Due to the extraordinary situation with the Covid-19 pandemic, the Board has found it necessary to urge shareholders to exercise their shareholder rights through advance votes by electronic communication via VPS Investor Services or to vote by proxy prior to the meeting and not attend the annual general meeting in person.
The notice including attendance and proxy forms will be mailed to all shareholders with known address. The complete notice, including the board of directors’ proposed resolutions for the items listed on the agenda, the recommendation of the nomination committee, the annual accounts and annual report for the financial year 2020, including the corporate governance report for 2020 and the guidelines for remuneration of executive management are attached to this notification and will also be made available at PCI Biotech's corporate website www.pcibiotech.com.
The notice including attendance and proxy forms, the board of directors’ proposed resolutions for the items listed on the agenda and the proposal from the nomination committee are attached hereto in both English and Norwegian.
For further information, please contact:
Ronny Skuggedal, CFO, E-mail: firstname.lastname@example.org
Office: +47 67 11 54 00 Mobile: +47 94 00 57 57
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
- PCI Biotech Holding ASA Innkalling GF 28 mai 2021
- PCI Biotech Holding ASA Forslag til vedtak GF 28 mai 2021
- PCI Biotech Holding ASA Notice of AGM 28 May 2021
- PCI Biotech Holding ASA Proposed resolutions for the AGM 28 May 2021
- PCI Biotech Proposal from the Nomination Committee 2021
- PCI Biotech Remuneration Policy
- PCI Biotech Holding ASA Annual Report 2020